RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to ...

Democratic Republic of Congo President Felix Tshisekedi has long ruled out dialogue with the Rwanda-backed M23 rebels ...

The Company Received Approval in Multiple European Countries to Initiate this Key Study Necessary for Commercial Product Approval RevBio, Inc., announced that it has received regulatory and ethics ...

While comprehensive two-dimensional gas chromatography coupled with mass spectrometry (GC×GC-MS) is a powerful analytical ...

Genocells is a new technology for fully genotyped herds, which rapidly identifies the main Somatic Cell Count (SCC) offender ...

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

Africa's drone revolution needs more than innovation—investing in ecosystems is key to bridging the infrastructure gap.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

But it would amount to an acknowledgment that Tshisekedi's pursuit of a military solution has "failed", said Congolese analyst Bob Kabamba of the University of Liege in Belgium. "Kinshasa's ...

The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celltrion stated in a news ...